2024 shaping up to be a strong year for biopharma
SAN FRANCISCO, Aug. 7, 2024 /PRNewswire/ — In the first half of 2024, 89% of US venture capital (VC) funds at or above $25M hit their fundraising targets, marking the second-highest rate in history, according to the latest report from Silicon Valley Bank (SVB), a division of First Citizens Bank. The 2024 report also found that the biopharma sector could be on track for a record-setting year after reaching high investment levels, particularly in larger deals, with 55 biopharma companies securing deals of $100M or more.
Leveraging 20 years of research and proprietary data analysis on healthcare venture trends, SVB’s 2024 Mid-Year Healthcare Investments and Exits Report analyzes venture capital investing, fundraising and exit activity across the healthcare sector.
The latest report found that VC fundraising in the first half of the year has found its footing, with fundraising forming a new baseline of just under an estimated $20B raised per year. As valuations remain under increased scrutiny, more than 1 in 4 of US healthcare companies that closed a venture capital deal of at least $15M in 2024 reported a flat or down round, according to SVB.
“Companies are still working to achieve growth that matches high pandemic-era valuations,” said Jackie Spencer, Head of Relationship Management for Life Science and Healthcare Banking at Silicon Valley Bank and author of the report. “While each sector has its own story to tell, it’s clear that 2024 activity shows investment in life sciences and healthcare is finding a path forward despite headwinds. With a continued focus on prioritizing profitability over growth and rationalizing valuations, we expect healthy and sustainable investment for the second half of the year.”
SVB’s mid-year report also provides in-depth analysis for sectors across healthcare including biopharma, healthtech, medical device, diagnostics/tools (dx/tools).
Key Findings:
Learn More
Read the complete 2024 Mid-Year Healthcare Investments and Exits report here: Healthcare Investments and Exits Mid-Year Report | Silicon Valley Bank (svb.com)
SVB is a leader in providing market insights on sectors across the innovation economy. For the complete library of SVB’s signature reports, please visit Market Research Industry Trends & Insights | Silicon Valley Bank (svb.com)
About Silicon Valley Bank
Silicon Valley Bank (SVB), a division of First Citizens Bank, is the bank of some of the world’s most innovative companies and investors. SVB provides commercial and private banking to individuals and companies in the technology, life science and healthcare, private equity, venture capital, and premium wine industries. SVB operates in centers of innovation throughout the United States, serving the unique needs of its dynamic clients with deep sector expertise, insights, and connections. SVB’s parent company, First Citizens BancShares, Inc. (NASDAQ: FCNCA), is a top 20 U.S. financial institution with more than $200 billion in assets. First Citizens Bank, Member FDIC. Learn more at svb.com.
SOURCE Silicon Valley Bank
Nationwide partner launches initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures…
PALO ALTO, CA / ACCESSWIRE / August 22, 2024 / Bioz, Inc., a pioneer in…
STOCKHOLM, SE / ACCESSWIRE / August 22, 2024 / PMD Device Solutions (FRA:8T0) (STO:PMDS) Press…
DATA SUPPORTING FDA APPROVAL PUBLISHED IN HIGH-IMPACT JOURNALPublication of results from ANGLE's Parsortix PC1 system…
POMONA, Calif., Aug. 21, 2024 /PRNewswire/ -- Pomona Community Health Center dba ParkTree Community Health Center…
MILPITAS, Calif., Aug. 21, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE:…